Nova Patents
RS51101B

Ncv ns3 protease inhibitors

Abstract

A compound of formula (I): wherein: the ipiq 1; R 1 is CONR10SO2R6; R2 is C1-C6 alkyl or C2-C6 alkenyl, wherein said alkyl or alkenyl optionally substituted with 1 to 3 halo; R ​​3 is C 1 -C 8 alkyl or C3-C8 cycloalkyl; R5 is H; R6 is C3-C6 cycloalkyl, Y is C (= 0); Z is O; M is C1-C12 alkylene or C2-C12 alkenylene; each entry R10 is independently H or C1-C6 alkyl; or a pharmaceutically acceptable salt or hidrat.Prijava contains 16 claims.

RS51101B, drawing sheet 1
Sheet 1 of 109

Term

No projected expiry on record.

  1. Priority
  2. Filed
  3. Granted
  4. Today

17 claims: 4 independent, 13 dependent

  1. 1
    Compound of formula (I):1. Jedinjenje formule (I): characterized in that: naznačeno time što: i p i q su 1;R1 je CONR10SO2R6;ipiq su 1;R1 is CONR10SO2R6;R2 is C 1 -C 6 alkyl or S2-Sb alkenyl, said alkyl or alkenyl being optionally substituted with 1 to 3 halo;R2 je СгСб alkil ili С2-Сб alkenil, pri čemu je navedeni alkil ili alkenil izborno supstituisan sa 1 do 3 halo;R3 is C1-Cs alkyl or C3-Cs cycloalkyl;R3 je C|-Cs alkil ili C3-Cs cikloalkil;RNo 5jeH;RЧ 5jeH;R6jeC3-C6 cikloalkil;R6jeC3-C6 cycloalkyl;Y is C (= O);YjeC(=O);Z is 0;Zje 0;M is C1-C12 alkylene or C2-Ci2 alkenylene;and each R10 is independently H or C 1 -C 6 alkyl;or a pharmaceutically acceptable salt or hydrate thereof. M je C|-C]2 alkilen ili C2-Ci2 alkenilen;i svako R10 je nezavisno H ili Cj-Сб alkil;ili njegova farmaceutski prihvatljiva so ili hidrat.
  2. 10
    A pharmaceutical composition comprising an effective amount of a compound according to any one of claims 1-9 or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier. 10. Farmaceutska kompozicija naznačena time što sadrži efikasnu količinu jedinjenja prema bilo kom od patentnih zahteva 1-9 ili njegove farmaceutski prihvatljive soli ili hidrata, i farmaceutski prihvatljiv nosač. 51101Β 51101Β
  3. 13
    A compound according to any one of claims 1-9, or a pharmaceutically acceptable salt or hydrate thereof, for use in therapy. 13. Jedinjenje prema bilo kom od patentnih zahteva 1-9 ili njegova farmaceutski prihvatljiva so ili hidrat, za primenu u terapiji.
  4. 14
    Use of a compound according to any one of claims 1-9, or a pharmaceutically acceptable salt or hydrate thereof, in the preparation of a medicament for the prevention or treatment of HCV infection in a subject in need thereof. 14. Primena jedinjenja prema bilo kom od patentnih zahteva 1-9 ili njegove fannaceutski prihvatljive soli ili hidrata, u pripremi leka za prevenciju ili lečenje HCV mfekcije kod subjekta kod koga postoji potreba za tim.
Independent claims4